#USA #Atrial Fibrillation #La Jolla, California #Rhythm AI #STAR Apollo

Rhythm AI's STAR Apollo Mapping Technology Success Story

In a groundbreaking study presented at the HRX 2026 conference, Rhythm AI has unveiled its latest findings from the STAR Apollo study. This MedTech company's innovative approach to mapping technology is proving to be a game changer in the treatment of atrial fibrillation (AF), particularly in patients who have already undergone ablative procedures.

The Significance of the Study

Rhythm AI's STAR Apollo Mapping Technology employs an advanced algorithm known as Stochastic Trajectory Analysis of Ranked Signals. This technology assists electrophysiologists in pinpointing the origins of atrial fibrillation by utilizing principles of activation timing that have been trusted in the field for years. This study included 50 patients from four U.S. centers who were undergoing redo ablation for persistent AF, showcasing the system's efficacy and safety profile.

Key Findings

The results were promising:

• - 100% procedural feasibility was achieved across the board.
• - An impressive 90% of patients were free from atrial fibrillation one year after the procedure.
• - A staggering 73% of patients showed no recurrence of arrhythmia.
• - Only minimal targeting of AF sites was necessary, indicating precision in the mapping process.
• - The safety profile was robust, with no recorded deaths or serious complications as a result of the procedure.
• - Furthermore, the use of STAR mapping added little operational time, with a median procedure duration of just over two hours.

Expert Insights

Dr. Dhanunjaya R. Lakkireddy, the Executive Medical Director of the Kansas City Heart Rhythm Institute, shared his insights, highlighting the challenges involved when initial ablation efforts fail. He stated, STAR Apollo provides a reliable method for identifying additional targets beyond traditional strategies, utilizing existing lab equipment in an innovative way. This approach has optimized the management of atrial fibrillation, and the results from the STAR Apollo study reflect its potential to positively transform treatment protocols.

Looking Forward

The encouraging results from STAR Apollo are critical as Rhythm AI prepares to broaden accessibility to this technology for physicians and patients alike. Mike Dineen, the President and CEO of Rhythm AI, emphasized the significance of these findings for clinical practice and the expanding deployment of their mapping technology.

Rhythm AI's commitment to improving AF outcomes signifies a vital step forward for patients who have historically been underserved by existing electrophysiology approaches. This FDA-cleared solution not only enhances the accuracy of mapping but also amplifies the effectiveness of procedural interventions for atrial fibrillation.

Conclusion

As Rhythm AI continues to refine and expand the application of the STAR Apollo Mapping Technology, the medical community can look forward to more advancements in treating atrial fibrillation. The positive initial outcomes underline the importance of innovation in medical technology, promising better health outcomes for millions affected by this common yet complex condition. Future evaluations and real-world applications of the STAR Apollo technology will be critical in shaping the next generation of AF management.